BioSpace News Archive

Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 7:40 a.m. ET (12:40pm GMT).

Freudenberg Medical, a global developer and manufacturer of medical devices, components, and minimally invasive solutions, has launched a major innovation initiative - backed by a multimillion-dollar annual investment in R&D - over all its business entities.

InDex Pharmaceuticals Holding AB announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19.

Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in China to provide promising immunotherapy

ITM Isotopen Technologien München AG and Chengdu Gaotong Isotope Co., Ltd. announced that they have signed a technology license agreement for the production and distribution of ITM Germanium-68/Gallium-68 Generators and no-carrier-added Lutetium-177 in China.

KarXT Demonstrated Statistically Significant and Clinically Meaningful Improvement in Total PANSS Score at All Time Points Over Five Weeks and was Well-Tolerated Compared to Placebo

Biedermann Motech, the leader in pedicle screw technology and pioneer in the spinal market for more than 30 years, announced the publication of initial clinical data in relation to its iMAS360 Procedure.

Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC

Today, at the ISSA Show North America 2019 annual conference, CloroxPro announced a partnership with leading non-profit Project for Public Spaces that will help advance its mission to improve public health by connecting individuals and empowering them to thrive as a community.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (“Aerie”), today announced the signing of an agreement (the “Agreement”) for the acquisition of Avizorex Pharma, S.L. (“AVX Pharma” or “AVX”), a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease.